TrailBio

TrailBio is a biotechnology company focused on the development of next-generation TRAIL (TNF-related apoptosis-inducing ligand) receptor agonists for oncology. The company utilizes a proprietary platform to engineer multi-valent proteins that aim to overcome the limitations of previous TRAIL-targeted therapies, such as low potency and poor pharmacokinetics. By specifically activating the extrinsic apoptosis pathway through TRAIL-R1 and TRAIL-R2, TrailBio seeks to provide a selective and effective treatment for various solid tumors. The leadership team includes veterans from NewLink Genetics who have extensive experience in bringing oncology candidates through clinical development. Their pipeline currently features candidates designed to optimize the therapeutic potential of the TRAIL pathway in combination with other anti-cancer agents.